Why is Kilitch Drugs falling/rising?

As of 29-Aug, Kilitch Drugs (India) Ltd is experiencing a decline in its stock price, currently at Rs 339.10, which reflects a decrease of Rs 10.55 or 3.02%. The stock has been underperforming significantly, having fallen for six consecutive days, resulting in a total decline of 18.78% during this period. Today, it opened with a loss of 4.98% and reached an intraday low of Rs 332.25. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite these negative trends, there has been a notable increase in investor participation, with delivery volume rising by 264.19% against the 5-day average. The company maintains a low debt-to-equity ratio and has shown healthy long-term growth, with net sales increasing at an annual rate of 31.41% and operating profit at 72.48%.
In the broader market context, Kilitch Drugs has underperformed the Sensex, with a 1-week return of -16.26% compared to the benchmark's -1.84%. Over the past month, the stock has declined by 22.93%, while the Sensex has only dropped by 1.88%. Although the stock has generated a slight return of -0.40% over the past year, its profits have risen significantly by 122.7%, indicating potential for recovery. The stock is currently trading at a discount compared to its peers' average historical valuations, which may suggest a fair valuation despite the recent price declines.